WO2024158159A1 - Device for improving blood sugar control ability using electrical stimulation - Google Patents

Abstract

Disclosed is a device and method for improving blood sugar control ability using electrical stimulation. The present invention comprises: a pair of pads attached to the skin in the form of a patch or tape coated with adhesive conductive hydrogel to be attached to the upper and lower circumferences of the abdomen; and a control module which outputs a control signal so that the pads operate at a set microcurrent and a set frequency within a set operating time. The microcurrent is configured to be set in 50 ㎂ increments in the range of 200-400 ㎂, the frequency is configured to be set in 10 Hz increments in the range of 1-60 Hz, and the set time is configured to be set in 10-minute increments in the range of 10 minutes-2 hours, thus having the effect of lowering fasting blood sugar or improving blood sugar control ability through electrical stimulation in case of impaired glucose tolerance or impaired fasting glucose.

Description

Device for improving blood sugar control ability using electrical stimulation

The present invention relates to a device for improving and lowering blood sugar levels. More specifically, the present invention relates to a device for improving and lowering blood sugar levels. More specifically, the present invention relates to a device for improving and lowering blood sugar levels by performing electrical stimulation for 4 weeks in a type 2 diabetes disease mouse model and small animals with high levels of insulin resistance to identify blood sugar-related indicators. It relates to a device and method for improving blood sugar control ability using electrical stimulation to lower fasting blood sugar or improve blood sugar control ability through stimulation.

In modern society, excessive food intake, lack of exercise, and irregular meals due to westernized eating habits, artificial sweeteners, and lack of sleep cause elevated blood sugar levels. It also causes overweight, which threatens health, and diabetes, which has a high mortality rate. Obesity requires constant treatment as it causes increased insulin resistance, type 2 diabetes, and various complications. Current blood sugar management methods include exercise therapy, diet control, intermittent fasting, drug treatment, and intake of health functional foods to reduce body fat percentage, improve blood circulation and insulin resistance, thereby suppressing the incidence of obesity and type 2 diabetes. However, exercise therapy and diet alone have limitations, and intermittent fasting is reported to be largely ineffective. Health functional foods must be consumed over a long period of time. Drug treatment is problematic due to serious side effects such as congestive heart failure, osteoporosis, pancreatitis, and severe hypoglycemia.

Meanwhile, microcurrent refers to a weak current of less than about 1,000 microamps (μA), which is a weak current similar to the weak biological current of about 40 to 60 μA flowing in the human body. It is known that the human body's biological current plays a role in maintaining health by transmitting information between the cerebrum and organs and promotes metabolism and blood circulation, ultimately enhancing natural healing power. Because microcurrent is within the body's own physiological current range, muscle contraction does not occur, it is sensuously comfortable, there is no electrical discomfort, excellent stability, and it has the advantage of having almost no side effects on the human body even when used for a long time. Previous studies using microcurrent have presented evidence through clinical trials on the various effects of microcurrent that microcurrent stimulation activates tissue healing and recovery processes and increases intracellular ATP resynthesis, protein synthesis, and DNA replication rates. there is.

Therefore, a therapeutic effect can be expected by using microcurrent stimulation to compensate for the side effects or problems of chemical ingredients and induce restoration to the normal state.

The prior art of a device for improving blood sugar is disclosed in KR Registration Patent Publication No. 10-0918776.

This prior art uses a blood sugar suppressing composition containing gallate catechin to long-term suppress the rise in blood sugar after a meal, and is a method of reducing the rise in blood sugar after a meal by inhibiting the absorption of sugar from the gastrointestinal tract through a mechanism of action different from that of existing hypoglycemic agents. It's about.

To solve these problems, the present invention provides a device and method for improving blood sugar control ability using electrical stimulation that can improve blood sugar control ability in a non-pharmacological method with fewer side effects by using microcurrents of similar intensity to biological currents. The purpose is to

Another object of the present invention is to provide a device and method for improving fasting blood sugar and blood sugar control ability using electrical stimulation in a non-invasive, non-pharmacological manner. .

The present invention to solve these problems is a device for improving blood sugar control ability using electrical stimulation that can improve blood sugar control ability in a non-pharmacological method with fewer side effects by using microcurrents of similar intensity to biological currents. It is attached to the skin. a pair of pads, a control module that outputs a control signal so that the pad operates at a set microcurrent and a set frequency within a set operating time, and a microcurrent that causes the pad to operate according to the setting data of the microcurrent transmitted from the control module. This can be achieved by comprising a current generator that outputs a constant current waveform to the pad, and a frequency generator that outputs a frequency waveform to the pad to drive the pad according to the frequency setting data transmitted from the control module. .

The control module further includes a key input unit that can set one or more of microcurrent, frequency, or setting time, and the microcurrent is configured to be set in 50㎂ increments in the range of 200 to 400㎂, and the frequency setting is It is configured to be set in the range of 1~60Hz in 10Hz increments, and the setting time is configured to be set in the range of 10 minutes to 2H in 10 minute increments.

The microcurrent is 400 μA, the frequency is 10 Hz, and the set time is 40 minutes. It is conducted 5 times a week for 4 weeks. Stimulation is applied repeatedly depending on the patient's condition. A glucose tolerance test is performed 12 hours before the test. After fasting, glucose is administered orally at a dose of 2g/kg, and blood is collected from the caudal vein at intervals of 0, 30, 60, and 120 minutes to measure the glucose concentration in the blood to test the glucose load.

In addition, after applying the electrical stimulation, the stimulation is terminated and fasting is performed for 12 hours, and then fasting blood sugar can be measured.

The pads are provided as a pair and are made in the form of a patch or tape coated with adhesive conductive hydrogel to be attached to the upper and lower abdomen to lower fasting blood sugar or improve blood sugar control ability. It has an adhesive component so that the surface can be used by attaching it to the skin.

Therefore, according to the apparatus and method for improving blood sugar control ability using electrical stimulation of the present invention, it is possible to lower fasting blood sugar or improve blood sugar control ability in cases of impaired glucose tolerance or impaired fasting blood sugar through electrical stimulation.

1 is a main configuration diagram of a device for improving blood sugar control ability using electrical stimulation according to an embodiment of the present invention;

Figure 2 is a type 2 diabetes disease mouse model;

Figure 3 is a diagram illustrating a high-fat diet model (high-insulin resistance symptom development model);

and

Figure 4 is a graph of experimental results for specific microcurrent values.

Terms or words used in this specification and claims are not to be construed limited to their ordinary or dictionary meanings, and the inventor can appropriately define the concept of terms to explain his or her invention in the best way. It must be interpreted based on the meaning and concept consistent with the technical idea of the present invention.

Throughout the specification, when a part is said to “include” a certain element, this means that it may further include other elements rather than excluding other elements, unless specifically stated to the contrary. In addition, terms such as "... unit", "... unit", "module", and "device" used in the specification refer to a unit that processes at least one function or operation, which is implemented through a combination of hardware and/or software. It can be.

Throughout the specification, the term “and/or” should be understood to include all possible combinations from one or more related items. For example, “the first item, the second item and/or the third item” means not only the first, second or third item, but also the meaning that may be derived from two or more of the first, second or third items. It means a combination of all possible items.

Hereinafter, an embodiment of the present invention will be described with reference to the drawings.

First, one feature of the present invention is to provide a device for improving blood sugar control ability using electrical stimulation that can improve blood sugar control ability in a non-pharmacological method with fewer side effects by using a microcurrent of similar intensity to biological current.

To this end, the present invention performs electrical stimulation for 4 weeks in mouse models of type 2 diabetes and small animals with high levels of insulin resistance to identify blood sugar-related indicators, thereby lowering fasting blood sugar or improving blood sugar control through electrical stimulation. I was able to confirm that it could be done.

In other words, the present invention applies microcurrents in cells and nerves that are out of the normal range due to pain or inflammation from the outside to compensate for the side effects or problems of chemical ingredients and induces restoration to the normal state. Microcurrent stimulation treatment is used, which is expected to be effective.

Figure 1 is a main configuration diagram of a device for improving blood sugar control ability using electrical stimulation according to an embodiment of the present invention. As shown, the device for improving blood sugar control ability 100 of the present invention is capable of setting the frequency and operation time. It may be configured to include a control module 110 and a pair of pads 120 that are electrically connected to the control module 110 and attached to the skin to apply a microcurrent.

The control module 110 is configured to set the range, frequency, and operation time of the microcurrent.

For this purpose, the control module 110 is equipped with a key input unit 130 to set micro current, frequency, and setting time.

Micro-current stimulation (MCS) refers to a weak current of less than about 1,000 microamps (μA), and is a current of similar intensity to the weak biological current of about 40 to 60 μA flowing in the human body. MCS is a method of inducing physiological effects through activation of the cells themselves rather than tissue units.

Specifically, the key input unit 130 includes a key for setting the range of microcurrent from 200 to 400 ㎂ in 50 ㎂ increments, a key for setting the frequency in 10 Hz increments from 1 to 60 Hz, and 10 for 10 minutes to 2H. It may be equipped with a key to set the time in minutes.

In addition, keys that can turn the power on and off of the device for improving blood sugar control ability of the present invention can be provided as well as keys that can repeatedly set the number of stimulations.

The display unit 140 is configured as a display that displays the setting process and operation process under the control of the control module 110.

The power supply unit 150 is a device for supplying power to the device for improving blood sugar control ability using electrical stimulation of the present invention and can be configured as a rechargeable battery or as an adapter that directly receives AC power and supplies the necessary DC power.

The pads 120 are provided in pairs and are attached to the left and right and/or above and below the lesion to be treated.

A pair of pads 120 is used in the form of a patch or tape coated with adhesive conductive hydrogel to be attached to the upper and lower abdomen to lower fasting blood sugar or improve blood sugar control ability of the present invention. do.

In particular, conductive hydrogel has an adhesive component that allows the surface to be used by attaching it to the skin.

also, Of course, the pad 120 can be a conventional adhesive patch that can be attached to the skin.

When power is applied through the key input unit 130, the control module 110 operates to apply a stimulation signal to the pad 120 according to the intensity and frequency of the current set in the key input unit and the operating time.

To this end, the current generator 114 operates to apply the relevant micro-current to the pad 120 according to the set micro-current data transmitted from the control module 110, and the related frequency is applied to the pad 120 according to the data of the set frequency. It is provided with a frequency generator 112 that operates to be applied to.

The current generator 114 operates to output the power applied from the power supply unit 150 to the pad 120 in the form of a fine constant current waveform according to the fine current setting data transmitted from the control module 110.

That is, the pad 120 operates to apply stimulation to the skin area to be stimulated by the waveform of the fine constant current applied from the current generator 114.

The micro-current setting data is configured to be set in 50 ㎂ increments in the range of 200 to 400 ㎂, corresponding to biological micro-current, through the key input unit 130.

The frequency generator 112 is a device that generates low frequencies to provide electrical stimulation to the location of the lesion. By using a control signal from the control module 110, the pad 120 stimulates the skin at a frequency set through the key input unit. It runs.

The control module 110 controls the frequency generator 112 according to the frequency input through the key input unit 130, and the frequency generator 112 controls body parts according to the frequency data transmitted by the control module 110. Generates a low-frequency waveform suitable for

These frequency settings are configured to be set in 10Hz increments in the range of 1~60Hz.

Meanwhile, the control module 110 stores operation time, current, frequency, or number of repetitions for each user (hereinafter referred to as user-specific setting data) according to the severity of the lesion, and transmits the information to the external terminal 200 through the communication unit 116. When managing by transmitting setting data for each user or transmitting data set in the terminal 200, the control module 110 controls the current generator 114 and the frequency generator 112 based on the received data. Thus, the pad 120 is controlled to operate at a set frequency and current within a set time.

To this end, the communication unit 116 holds a unique ID for each device and allows data to be exchanged based on the unique ID when transmitting and receiving data with the external terminal 200, and the terminal 200 is provided with the electrical stimulation of the present invention. Provide an application for controlling or setting a device for improving blood sugar control ability, run the application, enter the unique ID of the device to be controlled, and then set setting data for each user and transmit it to the device for improving blood sugar control ability of the present invention. In this case, if the unique ID is the same in the received data, one or more devices for improving blood sugar control ability that have received the corresponding signal can control the pad based on the received setting data for each user.

Separately, the control module 110 stores setting data for each user by allowing the user to input a unique ID (resident registration number, phone number, etc.). When the power is turned on, the control module 110 displays the information on the display unit 140. A unique identification name (e.g., name) corresponding to each user's unique ID is displayed so that the user can easily refer to it when reusing it in the future.

In addition, the control module 110 is configured so that the setting time can be set in 10-minute increments in the range of 10 minutes to 2H through the key input unit, and the number of repetitions can also be set.

As described above, the present invention allows the pad to be controlled with a set time, set frequency, and set intensity of microcurrent according to the blood sugar control ability of each user.

In other words, stimulation is applied by setting the intensity, frequency, and operation time of the current according to the size and symptoms of the lesion.

The reason why the intensity of stimulation varies is because the skin impedance value is different for each person, so in order to deliver the target intensity, if the impedance is high, the intensity of the current may be increased, and if the impedance is low, the intensity of the current may be weakened.

Therefore, our research team conducted an experiment by applying stimulation through a stimulation device made based on impedance feedback, and set the optimal conditions as follows.

The intensity of the current is a microcurrent stimulation condition that can actually produce an effect, and the range of the microcurrent is set to 200 to 400㎂ in 50㎂ increments.

In particular, skin impedance, which is the resistance component of the skin, is a major cause of reducing the effectiveness of stimulation. This skin impedance varies from person to person, and even for the same user, it changes depending on the skin condition at the time of use, duration, etc., so the same stimulation is applied. However, since the effect may vary depending on the user, the optimal frequency range is set to 200~400㎂.

In addition, several scholars have revealed that a small current, that is, a small current in the ㎂ unit, is more effective in treatment than a high-intensity current.

Since this type of microcurrent stimulation is of a magnitude that the user cannot feel, the user's random selection method is not appropriate, so it is configured to be automatically adjusted within the stimulation device.

The frequency ranges from 1 to 60Hz and can be set in 10Hz increments.

The reason for specifying the frequency in this way is to ensure that the electrical stimulation is delivered to the core.

Electrical conductivity and dielectric constant are obtained by changing the frequency of stimulation from 10 Hz to 20 GHz in human and animal tissues, and within this range, the International Commission of Non-Ionizing Radiation Protection (ICNIRP) in 2010 According to the guidelines presented in 2012, the frequency magnitude and exposure time were determined within a range where unpredictable adverse reactions to cells or cartilage tissue did not occur when applied.

Among these, 10Hz was selected, which is a frequency range that is safe to stimulate skin tissue and has a specific effect on cells, based on previous cell experiment results.

The setting time can be set in 10-minute increments between 10 minutes and 2 hours.

To achieve the full effect of stimulation, more than 30 minutes are needed, and the reason for limiting it to less than 1 hour is that long-term electrical stimulation can cause side effects on the skin.

In other words, the size of the frequency and exposure time were determined within a range where unpredictable abnormal reactions in cells or skin tissue did not occur.

In addition, the intensity of stimulation must change depending on the skin impedance, but this skin impedance is different for each person and even for the same user, it changes depending on the skin condition at the time of use, duration, etc., so even if the same stimulation is applied, the effect may vary for each user, so it can be effective for all users regardless of age or gender. It should be noted that the above-mentioned microcurrent, frequency, and setting time have been determined because they must vary depending on the patient.

As described above, the present invention is intended to improve fasting blood sugar disorders or impaired glucose tolerance by using microcurrent stimulation since impaired fasting blood sugar or impaired glucose tolerance can be a cause of diabetes.

The device for improving blood sugar control ability using electrical stimulation of the present invention may be selected from the group of medical devices consisting of low-frequency, far-infrared rays, steamers, massagers, cupping devices, braces, wheelchairs, and protectors, but is not limited thereto.

Hereinafter, the present invention will be described in more detail through the following experimental examples. However, this is intended to aid understanding of the present invention, and is not intended to limit the scope of the present invention.

[Experimental example]

Experimental Example 1

(Evaluation of changes in blood sugar control ability through glucose tolerance test in mice with type 2 diabetes)

<Example 1> Sugar load test

db/db mice are known to be a type 2 diabetes animal model that develops resistance to leptin due to a mutation in the leptin receptor gene, resulting in uncontrolled appetite, resulting in obesity, and increased blood sugar levels as they grow. Twelve 5-week-old male db/db mice were used, and an adaptation period was provided for 7 days.

Four groups were randomly assigned to each group: a diabetic disease group (DB) to which no electrical stimulation was applied, a diabetic disease group to which 200 μA of electrical stimulation was applied (DB200), and a diabetic disease group to which 400 μA of electrical stimulation was applied (DB400). To apply electrical stimulation, conductive hydrogel electrodes were attached to the upper and lower abdomen of the mouse, and then electrical stimulation was applied at 200 and 400 μA with a biphasic current at a frequency of 10 Hz, respectively. Stimulation was performed 5 times a week, for 40 minutes/day. The circuit was conducted for 4 weeks. After 4 weeks of stimulation, a glucose tolerance test was conducted to test glucose tolerance, and the experimental animals fasted for 12 hours before the test. After oral administration of glucose at a dose of 2 g/kg, blood was collected through caudal vein at intervals of 0, 30, 60, and 120 minutes, and blood glucose concentration was measured.

The results of this experiment are illustrated in Figure 2.

Figure 2 is a diagram showing the results of a glucose tolerance test performed 4 weeks after electrical stimulation, which relates to a type 2 diabetes mouse model. As a result of comparing the fasting blood sugar values before glucose administration, the DB group that did not receive electrical stimulation showed the results. In comparison, it can be seen that the DB200 and DB400 groups that underwent electrical stimulation for 4 weeks showed lower fasting blood sugar levels.

In addition, as a result of examining whether electrical stimulation can alleviate the sudden increase in blood sugar (blood sugar spike) after glucose administration, it was observed that blood sugar level decreased relatively quickly in the group that received electrical stimulation compared to the DB group ( Blood sugar control ability ↑) can be achieved.

Experimental Example 2

(Evaluation of ability to improve fasting blood sugar in animal model with high insulin resistance caused by high-fat diet)

<Example 1> Fasting blood sugar test

Eighteen 5-week-old male C57BL6 mice were used, and fed a high-fat diet (60% of kcal) for 8 weeks to induce a high-insulin resistance animal model. Afterwards, 6 animals per group were randomly divided into three groups: high-fat diet intake group (HFD), high-fat diet intake group with 200 μA electrical stimulation (HFD200), and 400 μA electrical stimulation with high-fat diet intake group (HFD400). assigned.

Before electrical stimulation, fasting blood sugar levels were measured in all animals after a 12-hour fast.

To apply electrical stimulation to the HFD200 and HFD400 groups, conductive hydrogel electrodes were attached to the upper and lower abdomen of the mouse, and then electrical stimulation was applied at 200 and 400 μA with a biphasic current at a frequency of 10 Hz, respectively. It was conducted 5 times, 40 minutes per session, for 4 weeks. After stimulation was completed and fasting was conducted for 12 hours, fasting blood sugar was measured at the end of the experiment.

The results of this experiment are illustrated in Figure 3.

Figure 3 is a diagram illustrating a high-fat diet model (high-insulin resistance symptom development model). This experiment was an experiment using an animal model in which insulin resistance was highly expressed through long-term high-fat diet intake, and in the group that did not receive electrical stimulation, As the experiment period continued (after 4 weeks), fasting blood sugar increased, but on the other hand, the group that applied electrical stimulation maintained the fasting blood sugar level before the experiment even though they consumed the same diet.

This suggests that electrical stimulation for 4 weeks can alleviate the increase in fasting blood sugar caused by a high-fat diet.

In this experiment, the 200μA and 400μA electrical stimulation groups measured somewhat better, but the 400μA electrical stimulation was found to have a more noticeable reduction in blood neutral fat levels, showing the optimal overall effect.

Figure 4 is a graph of experimental results for specific microcurrent values, and is a table of results measuring triglycerides in serum as a result of measurements conducted together with the experiment in Figure 3.

Referring to the figure, blood neutral fat levels measured after the end of the experiment decreased in all groups that underwent electrical stimulation, but the reduction effect was more dominant in the 400μA electrical stimulation group than in the 200μA electrical stimulation group.

Blood triglyceride levels are known to be an indicator that affects blood sugar control ability, so the 400μA electrical stimulation group ultimately has an excellent effect on blood sugar control ability.

Although the present invention has been described in detail with respect to the described embodiments above, it is obvious to those skilled in the art that various changes and modifications are possible within the technical scope of the present invention, and it is natural that such changes and modifications fall within the scope of the appended patent claims.

The present invention relates to a device for improving and lowering blood sugar, and can be used in fields that can lower fasting blood sugar or improve blood sugar control ability using electrical stimulation.

Claims (6)

In the device for improving blood sugar control ability using electrical stimulation, which can improve blood sugar control ability in a non-pharmacological method with fewer side effects by using microcurrent of similar intensity to biological current, A pair of pads that attach to the skin; A control module that outputs a control signal to operate the pad at a set microcurrent and set frequency within a set operation time; A current generator that outputs a waveform of a fine constant current to the pad so that the pad operates according to the fine current setting data transmitted from the control module; and. a frequency generator that outputs a frequency waveform to the pad to drive the pad according to frequency setting data transmitted from the control module; A device for improving blood sugar control ability using electrical stimulation including. In claim 1, The control module is It further includes a key input unit that can set one or more of microcurrent, frequency, or set time, The microcurrent is configured to be set in the range of 200~400㎂ in 50㎂ increments, the frequency setting is configured to be set in the range of 1~60Hz in 10Hz increments, and the setting time is 10 minutes in the range of 10 minutes to 2H. A device for improving blood sugar control ability using electrical stimulation that can be set in units. In claim 2, A device to improve blood sugar control ability using electrical stimulation that is conducted 5 times a week, 4 weeks, with a microcurrent of 400μA, a frequency of 10Hz, and a set time of 40 minutes, and the stimulation is repeatedly applied depending on the patient's condition. In claim 3, After applying the electrical stimulation To test glucose tolerance, a glucose tolerance test is performed. Fast for 12 hours before the test, administer glucose orally at a dose of 2g/kg, and collect blood from the caudal vein at intervals of 0, 30, 60, and 120 minutes to determine the blood glucose concentration. A device for improving blood sugar control ability using electrical stimulation, which is characterized by measuring and testing glucose load. In claim 7, After applying the electrical stimulation A device for improving blood sugar control ability using electrical stimulation, characterized in that it evaluates the ability to improve fasting blood sugar by measuring fasting blood sugar after the stimulation ends and fasting for 12 hours. In claim 1, The pad is It is provided as a pair and consists of a patch or tape form coated with adhesive conductive hydrogel to be attached to the upper and lower abdomen to lower fasting blood sugar or improve blood sugar control ability. The hydrogel has an adhesive component. A device for improving blood sugar control using electrical stimulation that can be used by attaching the corresponding surface to the skin.

Images